Abbreviations & Acronyms ESBL = extended-spectrum beta-lactamase FQ = fluoroquinolone FQ-R = fluoroquinoloneresistant IQR = interquartile range NA = not assessed PSA = prostate-specific antigen TRUSBx = transrectal ultrasound-guided prostate biopsy Objectives: To estimate the prevalence of fluoroquinolone-resistant rectal flora in patients undergoing transrectal ultrasound-guided prostate needle biopsy and to identify the high-risk groups. Methods: From January 2015 to March 2016, rectal swabs of 557 men who underwent transrectal ultrasound-guided prostate needle biopsy were obtained from five institutions. Clinical variables, including demographics, rectal swab culture results and infectious complications, were evaluated. Univariable and multivariable analyses were used to identify the risk factors for fluoroquinolone resistance of rectal flora and infectious complications. Results: The incidence of fluoroquinolone-resistant and extended-spectrum betalactamase production was 48.1 and 11.8%, respectively. The most common fluoroquinolone-resistant bacteria was Escherichia coli (81% of total fluoroquinoloneresistant bacteria, 39% of total rectal flora), and 16 (2.9%) patients had infectious complications. Univariable and multivariable analysis of clinical parameters affecting fluoroquinolone resistance showed no factor associated with fluoroquinolone resistance of rectal flora. The clinical parameter related to infectious complications after prostate biopsy was a history of operation within 6 months (relative risk 6.60; 95% confidence interval 1.99-21.8, P = 0.002). Conclusions: These findings suggest that a risk-based approach by history taking cannot predict antibiotic resistance of rectal flora, and physicians should consider targeted antibiotic prophylaxis or extended antibiotic prophylaxis for Korean patients undergoing transrectal ultrasound-guided prostate biopsy because of high antibiotic resistance of rectal flora.
Introduction
Prostate cancer is one of the most important health concerns for men. TRUSBx is a standard procedure for the histological diagnosis of prostate cancer, and its complications include pain, hematuria, acute urinary retention and infection. 1 TRUSBx can lead to many infectious complications, such as urinary tract infection, prostatitis, epididymo-orchitis and, most significantly, sepsis. Despite the proven efficacy and guideline recommendations of FQ as a firstline agent for antibiotic prophylaxis, the incidence of infectious complications has increasingly risen over the past two decades. 2 A simultaneous increase in the incidence of infectious complications from FQ-R Escherichia coli has been reported, leading to the conclusion that post-TRUSBx infection is caused by growing FQ-R. [2] [3] [4] [5] 10.6-22.0% and 1.3-11.0%, respectively, in Western countries, and targeted antibiotic prophylaxis based on rectal swab results has been suggested as a feasible and cost-effective practice by several reports. [6] [7] [8] The selected approach (selective rectal swab with targeted antibiotic prophylaxis or alternative antibiotics) for patients with risk factors might be beneficial in countries with low antibiotic resistance of rectal flora. However, if the antibiotic resistance of the rectal flora is high, targeted or extended antibiotic prophylaxis might be beneficial to all patients before TRUSBx. Antibiotic resistance of rectal flora in the Asian population appears to be greater than that of Western countries; [9] [10] [11] However, there is no multicenter data to provide a reference to update the antibiotic prophylaxis in Korea.
In Korea, FQ is the most commonly used antibiotic prophylaxis for TRUSBx. The aims of the present study were: (i) to determine the prevalence of FQ-R rectal flora in patients undergoing TRUSBx by rectal swab cultures; and (ii) to identify high-risk groups of FQ-R rectal flora and infectious complications, using the risk-based approach, considering antibiotic prophylaxis by selective rectal swab.
Methods

Data collection
We carried out the present prospective, multicenter study in Korea from January 2015 to March 2016. Groups at various centers throughout Korea were recruited (based on their motivation and commitment), to ensure a complete representation of members of the Korean Association of Urogenital Tract Infection and Inflammation. The study protocol (IRB approved protocol: No CNUHH-2014-154) was reviewed and approved by the institutional review board at each clinical site. The study was carried out in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies. All study participants read and signed an informed consent form. The indications for biopsy included elevated PSA levels or abnormal digital rectal examination findings. A 3-month recruitment period was planned, followed by 1 month of postbiopsy follow up.
A prebiopsy questionnaire was used to identify patient characteristics. Clinical variables including underlying disease, patient age, PSA levels, prostate volume, healthcare association, relationship with healthcare worker, history of travel within the past 4 weeks, history of operation, prostatitis within the previous 6 months, urinary tract infection within the previous 6 months, recent antibiotic exposure and prior prostate biopsy were recorded. Patients who were residents of any nursing home or long-term care facility, who were readmitted within 90 days of discharge from a previous hospitalization for ≥2 days or within 30 days before the onset of urinary tract infection, and had indwelling urethral catheters, had undergone any invasive urinary procedure, had received hemodialysis or intravenous chemotherapy on an outpatient basis or who had received specialized nursing care at home by qualified healthcare providers were categorized as having healthcare association. 12 Rectal swabs (KOMED, Sungnam, Korea) were plated directly onto MacConkey's agar (KOMED) with 1 lg/mL ciprofloxacin and incubated overnight at 37°C in ambient air. All isolates were characterized on the Vitek 2 using the GN and AST-GN30 cards (bioM erieux, Durham, NC, USA) for identification and susceptibility testing, respectively. Rectal swab samples were obtained within 2 weeks before the administration of antibiotics and TRUSBx, and povidoneiodine rectal cleansing was carried out just before and after the biopsy. Ciprofloxacin-resistant Gram-negative isolates were subjected to identification and susceptibility testing by guidelines of the Clinical Laboratory Standards Institute. Patients whose rectal swab culture showed no growth were excluded from the present study. Peri-procedural data were also obtained on all patients, as was the number of biopsy cores, prophylactic antibiotics type, durations of antibiotic treatment, local anesthesia and rectal enema use, povidoneiodine rectal cleansing, infectious complications after biopsy, and pathological results.
Antibiotic prophylaxis before prostate biopsy
We recommended FQ protocols for <4 days in the present study, and advised physician discretion in their use. This recommendation is not consistent with the position statement of the American Urological Association; however, it is proven that non-Caucasian people are at an increased risk of infectious complications because of the potential for high exposure to antibiotics as medication or in meat, which might result in increased antibiotic resistance. 13 
Statistical analysis
Descriptive statistics were used for the patient characteristics and clinical preprocedural factors. Multivariate analysis was carried out using multiple logistic regression analysis, to examine the independent effects of demographic and preprocedural factors. All variables with suggestive P-values on univariate analysis were included in the multivariate analysis, and P < 0.05 was considered statistically significant.
Results
Demographics
Among the 595 patients, 38 patients whose rectal swab culture showed no growth were excluded from the analysis. Of the remaining 557 patients, the median patient age was 69 years (IQR 63-75). The median logarithmically adjusted PSA levels, and prostate volumes were 1.87 ng/dL (IQR 1.40-2.44) and 35 mL (IQR 26.5-47.0), respectively. Among all patients, 11.7% reported receiving antibiotics in the previous 6 months, and 2.7% had a history of prostatitis. The prevalence of healthcare-associated patients was 10.8%. Most of the patients received FQ (88.2%) as prophylactic antibiotics and underwent enema with rectal or oral agents (96.2%). All patients underwent povidone-iodine rectal cleansing despite the lack of official recommendation for this treatment before this study. Urologists and radiologists carried out 30.2 and 69.8% of the biopsies, respectively. The pathological results of the biopsies were benign in 61.2% of patients (Table 1) .
Culture results
E. coli was the predominant Gram-negative fecal isolate (n = 468, 84.0%), followed by Klebsiella (n = 23, 4.1%), Enterobacter (n = 6, 1.1%), Enterococcus (n = 8, 1.4%), Pseudomonas (n = 1, 0.2%) and others (n = 51, 9.2%). Total quinolone-resistant Gram-negative coliforms were detected in 48.1% (n = 268), and most were quinolone-resistant E. coli (n = 217, 81.0%). Coliforms expressing ESBL activity, conferring resistance to the extended-spectrum cephalosporins, such as ceftriaxone, were identified in 11.8% (n = 66) of the patient population (Table 1) .
Rates and risk factors of infectious complications
The overall infectious complication rate was 2.9%. Postbiopsy sepsis was identified in one patient (0.2%; Table 1 ). No infection-related deaths were observed. The clinical parameter associated with infectious complications after biopsy was a history of operation within 6 months (RR 6.60, 95% CI 1.99-21.8, P = 0.002; Table 2 ).
Association between clinical parameters and FQ resistance
In the present study, the univariable and multivariable analyses showed no definite clinical risk factor associated with FQ-R ( Table 3) .
Discussion
In the present study, we showed the high prevalence of FQ-R in the rectal swabs of men undergoing TRUSBx in Korea. However, this did not translate to a high postbiopsy infection rate, and there was no definite clinical factor associated with FQ-R. A history of operation within 6 months was the only clinical factor associated infectious complications after TRUSBx.
Along with increased prostate cancer screening by testing the serum PSA level, TRUSBx has increasingly been carried out for the histological diagnosis of prostate cancer. TRUSBx is considered a safe procedure, apart from the risk of infectious complications, especially sepsis.
14 Infection from TRUSBx is caused by the bacterial flora harbored in the rectum, introduced into the genitourinary system or into the bloodstream after perforation of the rectal mucosa with a biopsy needle. 15 FQs, as presented in this study, are the most common prophylactic antibiotics used in patients undergoing TRUSBx. FQs are broad-spectrum antibiotics mainly active against Gram-negative bacteria, penetrating well into the prostate, and resulting in a long-lasting urinary bactericidal activity. Despite the proven efficacy and guideline recommendations of FQ as a first-line agent for antibiotic prophylaxis, the incidence of postbiopsy infectious complications has continually increased. 2 The prevalence of antibiotic resistance of normal flora is increasing worldwide. According to a meta-analysis excluding Asian data, the overall prevalence of FQ resistance was 17.1% after prostate biopsy. 10 Antibiotic resistance of normal flora in the Asian population appears to be higher than that of European or North American populations. In that study, the incidence of FQ-R and ESBL production was 48.1 and 11.8%, respectively. According to a study carried out in Thailand, 92.3% patients undergoing TRUSBx reportedly showed FQ resistance in fecal flora.
11 Among Hong Kong Chinese men, a total of 199 of 371 patients (53.6%) carried antibioticresistant rectal flora, with 40.4 and 41.0% of patients having FQ-R and ESBL-producing bacteria, respectively. 9 Similar to the present study, the high prevalence of FQ-R bacteria and the current choice of FQ as a prophylactic antibiotic did not lead to high postbiopsy infection; however, the reason is currently inconclusive. The pharmacokinetics of FQ might influence this result with the route, dosage and timing of antibiotic administration, but the reason is currently inconclusive. 9 In our case, the results between rectal flora and lower infectious complication rate might be explained by povidoneiodine rectal cleansing and the duration of antibiotic prophylaxis. Despite the lack of official recommendation, as shown in our previous studies, a povidone-iodine rectal cleansing may reduce the infectious complication rate by reducing the bacterial load. 16, 17 In a Japanese study, FQ-R and ESBL-producing E. coli were detected in 9.8 and 5.9%, respectively, similar to studies reported in Europe and America. 5, 6, 8, 15, 18 These dissimilarities could be explained by the differences in the culture method of rectal swabs, and the regional difference in antibiotic susceptibilities within the same ethnicity. An increasing rate, of FQ resistance among Gram-negative bacteria has been reported globally, and this might be no exception. 19 A recent meta-analysis revealed that FQ resistance in rectal flora is a significant predictor of postbiopsy infection and suggested re-assessment of empirical antibiotic prophylactic methods. 10 Thus, targeted antibiotic prophylaxis may be needed before TRUSBx. Rectal swab cultures would be required, one to several weeks before TRUSBx, to determine the presence of FQ-R flora, and guide the antimicrobial prophylaxis. Recently, by using this practice, several studies have shown promising results in postbiopsy infection rates. 6, 7 However, several queries about the practical use of rectal swab cultures need to be considered. The optimal timing of cultures should be established. A study reported that screening 2 weeks before prostate biopsy showed no difference compared with screening immediately before biopsy. 20 Concerns about the necessity, logistics, and cost-effectiveness of rectal swab cultures in all patients still exist, and a selected approach for the patients with risk factors might have benefits. 21 However, the selected approach might depend on the prevalence of antibiotic-resistant rectal flora. In Korean patients, physicians should consider targeted antibiotic prophylaxis or extended antibiotic prophylaxis for patients undergoing TRUSBx because of the high antibiotic resistance of rectal flora.
Changing prophylactic antibiotic from FQ to some alternatives with low resistance rates in the rectal flora or extended antibiotic prophylaxis eliminates the need for rectal swab culture. Several studies using prophylactic antibiotics with amikacin, carbapenems and fosfomycin reported its successful use to reduce postbiopsy infectious complications. [22] [23] [24] In addition to changing prophylactic antibiotics, several strategies have been suggested to reduce postbiopsy infectious complications. One such practice is rectal cleansing with enema, which could also improve ultrasonographic visualization of the prostate. However, there is no definite clinical outcome advantage, and the procedure causes inconvenience and increased cost. 25 Rectal cleansing with povidone-iodine or chlorhexidine has been studied, but the results are currently inconclusive. 26 Using a smaller needle size also showed no definite advantages in pain, bleeding, and infectious complications. 27 Washing the prostate biopsy needle with povidone-iodine has shown no reduction in infectious complication rates. 28 As previously reported, the most common risk factor of postbiopsy infectious complication is previous antibiotics exposure. 29 Also, diabetes mellitus, immunosuppression, previous prostate biopsy, history of urinary tract infection, hospital employees and journeys to high FQ-R areas were reported to increase the risk of infectious complications. 30 As previously stated, the present study showed that a history of operation within 6 months tended to increase the incidence of infectious complications, after the procedure. These findings might be attributed to changes in the rectal flora as a result of hospitalization and recent exposure to antibiotics; thus, clinicians should consider selective preparation for patients with these risk factors before biopsy. These clinical situations should be considered carefully, particularly in high-risk patients, to reduce postbiopsy infectious complications.
In Asian countries, alternative targeted or extended antibiotic prophylaxis should be strongly considered as opposed to the preferred use of FQ as an antibiotic prophylaxis in Europe or North America. By rectal swab cultures, we should identify FQ-R patients before TRUSBx, and provide antibiotic prophylaxis individually. This might be useful for not only appropriate prophylaxis, but also for proper antibiotic selection when postbiopsy infection occurs. If possible, prophylactic agents should be replaced with alternative antibiotics or extended antibiotic prophylaxis in patients suspected of FQ-R, and the selection of antibiotics adjusted to local antibiogram, and monitored.
The current study had several limitations. Most institutions in Korea used MacConkey's agar with or without ciprofloxacin, but the present study used MacConkey's agar with 1 lg/ mL ciprofloxacin. The rates of quinolone resistance in the institutions that used MacConkey's agar with 1 lg/mL ciprofloxacin might be relatively higher than other institutions that used agar with 10 lg/mL ciprofloxacin. Therefore, further studies comparing culture methods will be required. The variation in FQ resistance among studies might reflect regional and temporal differences in antimicrobial susceptibility. Methodological differences between studies are also relevant. We designed the present study without other kinds of quinolones for antibiotic prophylaxis because of restrictions by the regulation of the National Health Insurance Corporation. Therefore, in practice, ciprofloxacin is commonly used for antibiotic prophylaxis in Korea. The present study was confined to populations from some parts of Korea; therefore, an additional area of future research could provide normative data for Korea.
In conclusion, by using selective media to isolate FQ organisms from the rectum before TRUSBx, we identified a high prevalence of FQ-R in 48.1% patients. A history of operation within 6 months was associated with infectious complications after TRUSBx. Despite the high FQ resistance of rectal flora, we cannot estimate appropriate risk factors. With these results, we might consider targeted antibiotic prophylaxis or alternatives like extended prophylaxis, as the antibiotic resistance of rectal flora is the main risk factor of infectious complications.
